Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Cancer Trials Ireland

🇮🇪Ireland

Country: 🇮🇪Ireland

Ownership: Private

Established: 1996-01-01

Employees: 11

Market Cap: -

Website: http://www.cancertrials.ie

Clinical Trials

Breast Cancer Proteomics and Molecular Heterogeneity

Recruiting

Conditions: Recurrent/Metastatic Breast Cancer
Primary Breast Cancer

First Posted Date: 2013-04-25

Last Posted Date: 2023-04-06

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 1780

Registration Number: NCT01840293

Locations: 🇮🇪
St. Vincent's University Hospital, Dublin 4, Ireland
🇮🇪
Beaumont Hospital, Dublin, Ireland

Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

Completed

Conditions: HER2 Negative Breast Cancer
Breast Cancer
HER2 Positive Breast Cancer

First Posted Date: 2013-04-25

Last Posted Date: 2025-07-08

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 330

Registration Number: NCT01840306

Locations: 🇮🇪
Bon Secours Hospital, Cork, Ireland
🇮🇪
Cork University Hospital, Cork, Ireland
🇮🇪
Letterkenny General Hospital, Donegal, Ireland

and more 8 locations

ANGIOPREDICT. ICORG 12-16, V3

Completed

Conditions: Advanced Colorectal Cancer

First Posted Date: 2013-04-02

Last Posted Date: 2023-04-06

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 76

Registration Number: NCT01822444

Locations: 🇩🇪
Private Practice Oncology, Speyer, Rhineland-Palatinate, Germany
🇩🇪
Medizinische Klinik III, Universitaetsklinikum, Aachen, Germany
🇩🇪
Onkologisches Zentrum, Deggendorf, Germany

and more 14 locations

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

Phase 3

Completed

Conditions: Adenocarcinoma of the Oesophagus
Oesophageal Tumours
Junctional Tumours
Adenocarcinoma of the Oesophago-gastric Junction
Oesophageal Cancer

Interventions: Radiation: (41.4 Gy/23 fractions)
Drug: Epirubicin
Drug: Cisplatin / Oxaliplatin
Drug: Paclitaxel
Drug: 5 Flourouracil/ Capecitabine
Drug: Carboplatin
Drug: Docetaxel
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-Fluorouracil

First Posted Date: 2012-11-15

Last Posted Date: 2022-09-30

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 377

Registration Number: NCT01726452

Locations: 🇩🇰
Rigshospitalet, Blegdamsvej 9, Denmark
🇫🇷
Centre Hospitalier Régional, Universitaire de Lille 2 Avenue Oscar Lambret, 59000, Lille, France
🇮🇪
Cork University Hospital, Cork, Ireland

and more 26 locations

Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4

Terminated

Conditions: Non-Small Cell Lung Cancer
Colorectal Cancer

First Posted Date: 2012-11-14

Last Posted Date: 2025-07-08

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 161

Registration Number: NCT01726309

Locations: 🇮🇪
Letterkenny General Hospital, Letterkenny, Donegal, Ireland
🇮🇪
Bon Secours Hospital, Cork, Ireland
🇮🇪
Cork University Hospital, Cork, Ireland

and more 7 locations

Ovarian Reserve in Premenopausal Breast Cancer

Terminated

Conditions: Breast Cancer
Premenopausal Breast Cancer

First Posted Date: 2012-11-14

Last Posted Date: 2025-07-08

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 216

Registration Number: NCT01726322

Locations: 🇮🇪
Beacon Hospital, Dublin, Dublin 18, Ireland
🇮🇪
Our Lady of Lourdes Hospital, Drogheda, Louth, Ireland
🇮🇪
Bon Secours Hospital, Cork, Ireland

and more 7 locations

Circulating miRNAs.

Completed

Conditions: Recurrent Breast Cancer
Breast Cancer
Newly Diagnosed Breast Cancer

First Posted Date: 2012-11-07

Last Posted Date: 2025-07-08

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 255

Registration Number: NCT01722851

Locations: 🇮🇪
Bon Secours Hospital, Cork, Ireland
🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇪
St James's Hospital, Dublin, Ireland

and more 4 locations

CharactHer. ICORG 12-09, V3

Terminated

Conditions: TNM Stage II-IV Breast Cancer
HER2-positive Breast Cancer

First Posted Date: 2012-11-07

Last Posted Date: 2025-07-08

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 130

Registration Number: NCT01722890

Locations: 🇮🇪
St. Vincents University Hospital, Dublin, Ireland
🇮🇹
Humanitas Cancer Centre Milan, Milan, Italy

Tarceva. ICORG 08-41

Completed

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2012-11-04

Last Posted Date: 2015-03-30

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 200

Registration Number: NCT01721252

Locations: 🇮🇪
Cork University Hospital, Cork, Ireland
🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇪
St James Hospital, Dublin, Ireland

and more 4 locations

A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer

Phase 2

Completed

Conditions: Gastro Oesophageal Cancer

Interventions: Drug: Oxaliplatin
Drug: Epirubicin
Drug: Docetaxel
Drug: Capecitabine

First Posted Date: 2012-10-19

Last Posted Date: 2013-01-10

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 35

Registration Number: NCT01710592

Locations: 🇮🇪
Mercy University Hospital, Cork, Ireland
🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇪
Mater Misericordiae University hospital & Mater Private Hospital, Dublin, Ireland

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy